



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

When Services May Be Eligible for Coverage

Coverage for eligible medical treatments or procedures, drugs, devices or biological products may be provided only if:

- Benefits are available in the member's contract/certificate, and
- Medical necessity criteria and guidelines are met.

Based on review of available data, the Company may consider chelation therapy for heavy metal toxicity to be **eligible for coverage**.

Patient Selection Criteria

The use of chelation therapy for heavy metal toxicity, including thalassemia with hemosiderosis, may be considered for coverage eligibility only when the following treatment parameters have been satisfied:

- Treatment complies with standard medical reference based on the blood level of the specific heavy metal identified; AND.
- The route of delivery of the chelation agent follows appropriate standard medical reference based on the specific heavy metal identified.

For example:

- o Mercury toxicity can be treated with oral agents
- o Parenteral edentate calcium disodium (EDTA) would be appropriate to treat lead toxicity in patients with blood lead levels of > 45µg/dL.

Based on review of available data, the Company may consider chelation therapy to be **eligible for coverage** for ANY of the following conditions:

- Control of ventricular arrhythmias or heart block associated with digitalis toxicity; OR
- Emergency treatment of hypercalcemia; OR
- Wilson's disease (hepatolenticular degeneration); OR
- Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and due to nontransfusion dependent thalassemia (NNTD).

Note:

For the first 2 bullet points, most patients should be treated with other modalities. Digitalis toxicity is currently treated in most patients with Fab monoclonal antibodies. FDA removed the approval for NaEDTA as chelation therapy due to safety concerns and recommended that other chelators be used. This was the most common chelation agent used to treat digitalis toxicity and hypercalcemia.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

When Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of chelation therapy when patient selection criteria are not met to be **investigational**.*

Based on review of available data, the Company considers the use of chelation therapy for non- Food and Drug Administration (FDA) approved indications to be **investigational**.*

Based on review of available data, the Company considers all other applications of chelation therapy, including but not limited to the following, to be **investigational***:

- Atherosclerosis (i.e., coronary artery disease, secondary prevention in patients with myocardial infarction, or peripheral vascular disease);
- Multiple sclerosis;
- Arthritis (includes rheumatoid arthritis);
- Hypoglycemia;
- Autism;
- Alzheimer's disease;
- Diabetes;
- Heavy metal toxicity, or iron or lead poisoning when toxic levels are not documented by blood levels.

Background/Overview

Chelation therapy, an established treatment for treating heavy metal toxicities, has been investigated for a variety of other applications including treatment of atherosclerosis, Alzheimer's disease, and autism.

Chelation therapy is an established treatment for the removal of metal toxins by converting them to a chemically inert form that can be excreted in the urine. Chelation therapy consists of the intravenous or oral administration of chelating agents that remove metal ions such as lead, aluminum, mercury, arsenic, zinc, iron, copper, and calcium from the body.

Specific chelating agents are used for particular heavy metal toxicities. For example, desferroxamine is used for patients with iron toxicity, and calcium-ethylenediaminetetraacetic acid (-EDTA) is used for patients with lead poisoning. Note that disodium-EDTA is not recommended for acute lead poisoning due to the increased risk of death from hypocalcemia. Another class of chelating agents, called metal protein attenuating compounds (MPACs), is under investigation for the treatment of Alzheimer's disease, which is associated with the disequilibrium of cerebral metals. Unlike traditional systemic chelators that bind and remove metals from tissues systemically, MPACs have subtle effects on metal homeostasis and abnormal metal interactions. In animal models of Alzheimer's disease, they promote the solubilization and clearance

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

of A β -amyloid protein by binding its metal-ion complex and also inhibit redox reactions that generate neurotoxic free radicals. MPACs therefore interrupt two putative pathogenic processes of Alzheimer's disease. However, no MPACs have received FDA approval for the treatment of Alzheimer's disease. Chelation therapy has also been discussed as a treatment for other indications including atherosclerosis and autism. For example, EDTA chelation therapy has been proposed in patients with atherosclerosis as a method of decreasing obstruction in the arteries.

FDA or Other Governmental Regulatory Approval

Calcium-EDTA was approved by the FDA for lowering blood lead levels among patients with lead poisoning. Disodium-EDTA was approved by the FDA for use in selected patients with hypercalcemia and for use in patients with heart rhythm problems due to intoxication with the drug, digitalis. In 2008, the FDA withdrew approval of disodium-EDTA due to safety concerns and recommended that other forms of chelation therapy be used.

Several iron chelating agents have received FDA approval. Deferoxamine for subcutaneous, intramuscular, or intravenous injections was approved for treating acute iron intoxication and chronic iron overload due to transfusion-dependent anemia. Deferasirox, approved in 2005, is available as a tablet for oral suspension and is indicated for the treatment of chronic iron overload due to blood transfusions in patient's age 2 years and older. Under the accelerated approval program, the FDA expanded approval of deferasirox in 2013 to include the treatment of patients age 10 and older with chronic iron overload due to nontransfusion-dependent thalassemia (NTDT). In 2011, the FDA approved the iron chelator deferiprone for the treatment of patients with transfusional overload due to thalassemia syndromes when other chelation therapy is inadequate. Deferiprone is available in tablet form for oral use.

Rationale/Source

Chelation therapy is an established treatment for the indications listed in the medically necessary policy statement, particularly for the treatment of metal toxicity and transfusional hemosiderosis. Thus, literature searches have focused on the use of chelation therapy for other conditions including, but not limited to, atherosclerosis, autism, Alzheimer's disease, multiple sclerosis, and diabetes.

Atherosclerosis

In 2002, a Cochrane review was published evaluating studies on EDTA chelation therapy for treating patients with atherosclerotic cardiovascular disease. Five placebo-controlled randomized-controlled trials (RCTs) were identified, none of which reported mortality, non-fatal events, and cerebrovascular vascular events. Four of the 5 studies (total n=250) found no significant benefits of EDTA chelation therapy on outcomes reported including direct or indirect measurement of disease severity and subjective measures of improvement. The fifth study, which included only 10 patients, was apparently stopped early due to benefit, but relevant outcome data were not available. The Cochrane reviewers concluded that there was insufficient evidence to draw conclusions of the efficacy of chelation therapy for treating atherosclerosis; additional RCTs that report health outcomes including mortality and cerebrovascular events were needed.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

Among the published RCTs, Knudtson and colleagues randomized 84 patients with coronary artery disease and a positive treadmill test to receive EDTA chelation therapy or placebo, 3 hours per treatment twice weekly for 15 weeks, and once per month for an additional 3 months. The main outcome measures included change in time to ischemia, functional reserve for exercise, and quality of life. There was no significant difference between the two groups. Another double-blind, randomized controlled study of EDTA chelation or placebo showed no change in short- or long-term improvement in vasomotor response to EDTA when compared to placebo. Two small randomized trials have also reported no benefit of chelation therapy as a treatment of peripheral arterial disease.

Section summary: Several RCTs have been published on chelation therapy for treating atherosclerosis; these have generally reported intermediate outcomes and have not found EDTA chelation therapy to be more effective than placebo. Additional RCTs that report health outcomes are needed to establish the efficacy of this treatment.

Autism

Based on similarities between mercury poisoning and autism spectrum disorder symptoms, Bernard and colleagues hypothesized a link between environmental mercury and autism. This theory was rejected by Nelson and Bauman, who found that many of the characteristics of mercury poisoning such as ataxia, constricted visual fields, peripheral neuropathy, hypertension, skin eruption, and thrombocytopenia, are never seen in autistic children. In 2007, a systematic review by Ng and colleagues concluded that there was no association between mercury poisoning and autism.

In 2009, Rossignol published a systematic review of novel and emerging treatments for autism and did not identify any studies that included a control group. The author stated the case series suggest that chelation might be a viable form of treatment in some autistic individuals with known elevated heavy metal levels and that this possibility needs to be further investigated in controlled studies.

Section summary: There is a lack of controlled studies on the effect of chelation therapy on health outcomes in patients with autism.

Alzheimer's Disease

A 2008 Cochrane Review evaluated MPAC for treating Alzheimer's disease. The review identified one placebo-controlled RCT. This study, by Richie and colleagues, was published in 2003. Patients were treated with PBT1, an MPAC also known as clioquinol, an anti-fungal medication that crosses the blood-brain barrier. Clioquinol was withdrawn for oral use in 1970 because of its association with subacute myelo-optic neuropathy. In the study, oral clioquinol was administered in doses increasing to 375 mg twice daily to 16 Alzheimer's disease patients, and the effects were compared to 16 matched controls who received placebo. At 36 weeks, there was no statistically significant between-group difference in cognition measured by the Alzheimer's Disease Assessment Scale – Cognitive (ADAS-Cog scale). One patient in the treatment group developed impaired visual acuity and color vision during weeks 31 to 36 while she was receiving clioquinol, 375 mg twice daily. Her symptoms resolved on treatment cessation.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

Further studies of PBT1 have been abandoned in favor of a successor compound, PBT2. Lannfelt and colleagues completed a double-blind, placebo-controlled RCT in which 78 Alzheimer's disease patients were treated for 12 weeks with 50 mg PBT2 (n=20), 250 mg PBT2 (n=29), or placebo (n=29). There was no statistically significant difference in ADAS-Cog scale or Mini-Mental Status Exam scores among groups in this short-term study. The most common adverse event was headache. Two serious adverse events (urosepsis and transient ischemic event) were reported, both by patients receiving placebo.

Ongoing investigations in chelation therapy for the treatment of Alzheimer's disease and other neurodegenerative diseases include linking a carbohydrate moiety to drug molecules to enhance drug delivery across the blood-brain barrier; this strategy may solve the potential problem of premature and indiscriminate metal binding. In addition, multi-function drugs that not only bind metal but also have significant antioxidant capacity are in development.

Section summary: There is insufficient evidence on the safety and efficacy of chelation therapy for treating patients with Alzheimer's disease. The few published RCTs did not find that the treatment was superior to placebo for improving health outcomes.

Diabetes

Cardiovascular disease in patients with diabetes

A 2009 trial by Cooper and colleagues in New Zealand evaluated the effect of copper chelation using oral trientine on left-ventricular hypertrophy in 30 patients with type 2 diabetes. A total of 21/30 (70%) of the participants completed the 12-month follow-up. At 12 months, there was a significantly greater change in left ventricular mass indexed to body surface area (LVM) in the group receiving active treatment compared to placebo (-10.6 g/m² vs. -0.1 g/m², p=0.01). The study was limited by the small sample size and high drop-out rate.

Diabetic nephropathy

Chen and colleagues in China investigated the effect of chelation therapy on the progression of diabetic nephropathy in patients with high-normal lead levels. Their 2012 single-blind study included 50 patients with diabetes, high-normal body lead burden (80-6,000 μ g) and serum creatinine 3.8 mg/dL or lower. At baseline, the mean blood lead level was 6.3 μ g/dL in the treatment group and 7.1 μ g/dL in the control group and the mean body lead burden was 151 μ g for patients in the treatment group and 142 μ g for patients in the control group. According to the U.S. Occupational and Health Safety Administration (OSHA), the maximum acceptable blood lead level in adults is 40 μ g/dL. Patients were randomized to 3 months of calcium disodium EDTA or placebo. During the following 24 months, patients in the chelation group received additional chelation treatments as needed (i.e., if serum creatinine level exceeded pre-treatment levels or body lead burden was >60 μ g) and patients in the placebo group continued to receive placebo medication. All patients completed the 27-month study. The primary outcome was change in estimated glomerular filtration rate (eGFR). The yearly rate of decrease in eGFR was 5.6 mL/min/173 m² (standard deviation [SD]: 5.0) in the chelation group and 9.2 mL/min/173 m² (SD: 3.6) in the control group. The difference between groups was statistically significant, p=0.04. The secondary endpoint was the number of

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

patients in whom the baseline serum creatinine doubled or who required renal replacement therapy. A total of 9 patients (36%) in the treatment group and 17 (68%) in the control group attained the secondary endpoint; the difference between groups was statistically significant ($p=0.02$). There were no reported side effects of chelation therapy during the 27-month study period.

Section summary: Two small RCTs with limitations represent insufficient evidence that chelation therapy is effective for treating cardiovascular disease in patients with diabetes. One small single-blind RCT is insufficient evidence that chelation therapy is effective for treating diabetic nephropathy in patients with high-normal lead levels. Additional RCTs with larger numbers of patients and that report health outcomes such as cardiovascular events, end-stage renal disease and mortality are needed.

Myocardial infarction (MI)

In 2013, findings of the randomized double-blind multicenter Trial to Assess Chelation Therapy (TACT) study were published. The study included 1,708 individuals, age 50 or older, who had a history of a myocardial infarction at least 6 weeks previous and a serum creatinine level of 2.0 mg/dL or less. Patients were randomized to receive 40 infusions of disodium EDTA ($n=839$) or placebo ($n=869$). The first 30 infusions were given weekly, and the remaining 10 infusions were given 2 to 8 weeks apart. The primary endpoint was a composite outcome that included death from any cause, reinfarction, stroke, coronary revascularization or hospitalization for angina at 5 years. A total of 361 patients in the chelation group (43%) and 464 patients in the placebo group (57%) discontinued treatment after starting it, withdrew consent during follow-up or were lost to follow-up. The Kaplan-Meier 5-year estimates for the primary endpoint were 32.8% (95% confidence interval [CI]: 29.1% to 36.5%) in the chelation group and 38.5% (95% CI: 34.6% to 42.3%) in the control group. The difference between groups was statistically significant; the p value was 0.035, which was below the significance threshold required due to multiple interim analyses, 0.036. The most common individual clinical endpoint was coronary revascularization, which occurred in 130 of 839 patients (15%) in the chelation group and 157 of 869 patients (18%) in the control group, p value=0.08. The next most frequent endpoint was death. This occurred in 87 of 839 (10%) of patients in the chelation group and 93 of 869 (11%) of patients in the placebo group, p value=0.64. None of the individual components of the primary outcome differed significantly between groups; however, the study was not powered to detect difference in individual components. Four severe adverse events occurred that were definitely or possibly related to study therapy. There were 2 events each in the treatment and control group, including 1 death in each group.

The study is limited by the low follow-up rate, including a greater number of patients who withdrew consent in the placebo group compared to the treatment group. The primary endpoint included components of varying clinical significance, with most of the difference between groups occurring for revascularization events. The primary endpoint barely met the significance threshold and if more patients had been retained in the study and experienced events, results could have differed. Moreover, as noted in an editorial accompanying the publication, 60% of patients were enrolled at centers described as complementary and alternative medicine sites, and this may have resulted in a population that is not generalizable to that seen in clinical care.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

Section summary: One RCT with limitations, including high dropout with differential drop-out between groups, reported that cardiovascular events are reduced in patients treated with chelation therapy. However, this was not a high-quality trial and therefore the results could have arisen from bias. Further trials that are of high quality are needed to corroborate whether chelation therapy improves outcomes in patients with prior MI.

Other potential indications

No RCTs or other controlled studies were identified that evaluated the safety and efficacy of chelation therapy for other conditions such as multiple sclerosis or arthritis.

Summary

Chelation therapy is an established treatment for the medically necessary indications listed in the policy statement, such as treatment of metal toxicity and transfusional hemosiderosis. There is insufficient evidence that chelation therapy improves health outcomes for patients with other conditions including, but not limited to, atherosclerosis, autism, Alzheimer's disease, diabetes and arthritis. Thus, chelation therapy for these other applications is considered investigational.

References

1. Blue Cross and Blue Shield Association, Medical Policy Reference Manual, "Chelation Therapy for Off-Label Uses", 8.01.02, 2:2017.
2. Centers for Disease Control and Prevention. Deaths associated with hypocalcemia from chelation therapy--Texas, Pennsylvania, and Oregon, 2003-2005. *MMWR Morb Mortal Wkly Rep* 2006; 55(8):204-7.
3. Food and Drug Administration. Hospira, Inc., et al.; Withdrawal of Approval of One New Drug Application and Two Abbreviated New Drug Application. Available online at: <http://www.fda.gov/OHRMS/DOCKETS/98fr/E8-13273.htm>. Last accessed May, 2013.
4. Villarruz MV, Dans A, Tan F. Chelation therapy for atherosclerotic cardiovascular disease. *Cochrane Database Syst Rev* 2002; (4):CD002785.
5. Knudtson ML, Wyse DG, Galbraith PD et al. Chelation therapy for ischemic heart disease: a randomized controlled trial. *JAMA* 2002; 287(4):481-6.
6. Anderson TJ, Hubacek J, Wyse DG et al. Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy. *J Am Coll Cardiol* 2003; 41(3):420-5.
7. Guldager B, Jelnes R, Jorgensen SJ et al. EDTA treatment of intermittent claudication--a double-blind placebo-controlled study. *J Intern Med* 1992; 231(3):261-7.
8. Van Rij A. M., Solomon C, Packer SG et al. Chelation therapy for intermittent claudication: A double-blind, randomized, controlled trial. *Circulation* 1994; 90(3):1194-9.
9. Bernard S, Enayati A, Redwood L et al. Autism: a novel form of mercury poisoning. *Med Hypotheses* 2001; 56(4):462-71.
10. Nelson KB, Bauman ML. Thimerosal and autism? *Pediatrics* 2003; 111(3):674-9.
11. Ng DK, Chan CH, Soo MT et al. Low-level chronic mercury exposure in children and adolescents: meta-analysis. *Pediatr Int* 2007; 49(1):80-7.
12. Rossignol DA. Novel and emerging treatments for autism spectrum disorders: A systematic review. *Ann Clin Psychiatry* 2009; 21(4-Jan):213-36.
13. Sampson E, Jenagaratnam L, McShane R. Metal protein attenuating compounds for the treatment of Alzheimer's disease. *Cochrane Database Syst Rev* 2008; (1):CD005380.
14. Ritchie CW, Bush AI, Mackinnon A et al. Metal-protein attenuation with Iodochlorhydroxyquin (clioquinol) targeting A β amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. *Arch Neurol* 2003; 60(12):1685-91.
15. Lannfelt L, Blennow K, Zetterberg H et al. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. *Lancet Neurol* 2008; 7(9):779-86.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

16. Cavalli A, Bolognesi ML, Minarini A et al. Multi-target-directed ligands to combat neurodegenerative diseases. *J Med Chem* 2008; 51(3):347-72.
17. Cooper GJ, Young AA, Gamble GD et al. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomized placebo-controlled study. *Diabetologia* 2009; 52(4):715-22.
18. Chen KH, Lin JL, Lin-Tan DT et al. Effect of chelation therapy on progressive diabetic nephropathy in patients with type 2 diabetes and high-normal body lead burdens. *Am J Kidney Dis* 2012; 60(4):530-8.
19. U.S. Department of Labor Occupational Health and Safety Administration (OSHA). Safety and Health Regulations for Construction. Available online at: http://www.osha.gov/pls/oshaweb/owadisp.show_document?p_table=STANDARDS&p_id=10642. Last accessed May, 2013.
20. Lamas GA, Goertz C, Boineau R et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. *JAMA* 2013; 309(12):1241-50.
21. Nissen SE. Concerns about reliability in the Trial to Assess Chelation Therapy (TACT). *JAMA* 2013; 309(12):1293-4.
22. American College of Physicians/American College of Cardiology Foundation/American Heart Association/American Association for Thoracic Surgery/Preventive Cardiovascular Nurses Association/Society of Thoracic Surgeons. Management of stable ischemic heart disease. Available online at: www.guideline.gov. Last accessed May, 2013.
23. Snow V, Barry P, Fihn SD et al. Primary care management of chronic stable angina and asymptomatic suspected or known coronary artery disease: a clinical practice guideline from the American College of Physicians. *Ann Intern Med* 2004; 141(7):562-7.
24. Hirsch AT, Haskal ZJ, Hertzner NR et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. *Circulation* 2006; 113(11):e463-654.

Policy History

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

- | | |
|------------|--|
| 06/20/2002 | Medical Policy Committee review. Format revision. No substance change to policy. |
| 06/24/2002 | Managed Care Advisory Council approval |
| 07/14/2005 | Medical Director review |
| 07/19/2005 | Medical Policy Committee review. Format revision. Rationale/Source added. Patient selection criteria defined and: "Heavy metal toxicity, or iron or lead poisoning when toxic levels are not documented by blood levels" added to investigational statement. |
| 08/24/2005 | Managed Care Advisory Council approval |
| 07/07/2006 | Format revision including addition of FDA and or other governmental regulatory approval and rationale/source. Coverage eligibility unchanged. |
| 09/06/2006 | Medical Director review |
| 09/20/2006 | Medical Policy Committee approval. No changes to policy guidelines. |
| 10/10/2007 | Medical Director review |
| 10/17/2007 | Medical Policy Committee approval. No change to coverage eligibility. |
| 10/01/2008 | Medical Director review |
| 10/22/2008 | Medical Policy Committee approval. No change to coverage eligibility. |
| 10/01/2009 | Medical Policy Committee approval |
| 10/14/2009 | Medical Policy Implementation Committee approval. Added that when patient selection criteria are not met, or if chelation therapy is used for non-FDA approved indications, to deny investigational. |
| 10/14/2010 | Medical Policy Committee review |

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

- 10/20/2010 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
 - 10/06/2011 Medical Policy Committee review
 - 10/19/2011 Medical Policy Implementation Committee approval. Autism and Alzheimer's disease added to investigational indications.
 - 10/11/2012 Medical Policy Committee review
 - 10/31/2012 Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
 - 02/04/2013 Coding revised
 - 10/03/2013 Medical Policy Committee review
 - 10/16/2013 Medical Policy Implementation Committee approval. "Treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) and due to nontransfusion dependent thalassemia (NTD)" was added as eligible for coverage. Investigational statements clarified.
 - 10/02/2014 Medical Policy Committee review
 - 10/15/2014 Medical Policy Implementation Committee approval. No change to coverage.
 - 12/03/2015 Medical Policy Committee review
 - 12/16/2015 Medical Policy Implementation Committee approval. No change to coverage.
 - 12/01/2016 Medical Policy Committee review
 - 12/21/2016 Medical Policy Implementation Committee approval. No change to coverage.
 - 01/01/2017 Coding update: Removing ICD-9 Diagnosis Codes
 - 12/07/2017 Medical Policy Committee review
 - 12/20/2017 Medical Policy Implementation Committee approval. No change to coverage. Note added.
- Next Scheduled Review Date: 12/2018

Coding

The five character codes included in the Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®)‡, copyright 2016 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.

The responsibility for the content of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines is with Blue Cross and Blue Shield of Louisiana and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Blue Cross Blue Shield of Louisiana Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code	Code
------	------

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

Type				
CPT	No codes			
HCPCS	J0470, J0600, J0895, J3490, J3520, M0300, S9355			
ICD-10 Diagnosis	A18.01-A18.02	D56.0-D56.9	D57.3	D57.40
	D57.411-D57.419	E08.3211-E08.3219	E08.3291-E08.3299	E08.3311-E08.3319
	E08.3391-E08.3399	E08.3411-E08.3419	E08.3491-E08.3499	E08.3511-E08.3519
	E08.3521-E08.3529	E08.3531-E08.3539	E08.3541-E08.3549	E08.3551-E08.3559
	E08.3591-E08.3599	E08.37X1-E08.37X9	E08.618	E08.649
	E09.3211-E09.3219	E09.3291-E09.3299	E09.3311-E09.3399	E09.3411-E09.3419
	E09.3491-E09.3499	E09.3511-E09.3519	E09.3521-E09.3529	E09.3531-E09.3539
	E09.3541-E09.3549	E09.3551-E09.3559	E09.3591-E09.3599	E09.37X1-E09.37X9
	E09.618	E10.10-E10.11	E10.21-E10.29	E10.311-E10.319
	E10.3211-E10.3219	E10.3291-E10.3299	E10.3311-E10.3319	E10.3391-E10.3399
	E10.3411-E10.3419	E10.3491-E10.3499	E10.3511-E10.3519	E10.3521-E10.3529
	E10.3531-E10.3539	E10.3541-E10.3549	E10.3551-E10.3559	E10.3591-E10.3599
	E10.36	E10.37X1-E10.37X9	E10.39	E10.40-E10.49
	E10.51-E10.59	E10.610	E10.618	E10.620-E10.628
	E10.630-E10.638	E10.641-E10.649	E10.65-E10.69	E10.8-E10.9
	E11.00-E11.01	E11.21-E11.29	E11.311-E11.359	E11.3211-E11.3219
	E11.3291-E11.3299	E11.3311-E11.3319	E11.3391-E11.3399	E11.3411-E11.3499
	E11.3511-E11.3599	E11.36-E11.39	E11.37X1-E11.37X9	E11.40-E11.49
	E11.51-E11.59	E11.610-E11.638	E11.641-E11.649	E11.65-E11.69
	E11.8-E11.9	E13.00-E13.29	E13.311-E13.359	E13.3211-E13.3219
	E13.3291-E13.3299	E13.3311-E13.3399	E13.3411-E13.3419	E13.3491-E13.3499
	E13.3511-E13.3519	E13.3521-E13.3529	E13.3531-E13.3539	E13.3541-E13.3549
	E13.3551-E13.3559	E13.3591-E13.3599	E13.37X1-E13.37X9	E13.40-E13.59
	E13.610-E13.649	E13.65-E13.69	E13.8-E13.9	E133.6-E133.9
	E15	E16.0-E16.1	E20.1	E83.00-E83.09
	E83.40-E83.59	F84.0	G30.0-G30.9	G35
	I25.10	I25.110-I25.119	I25.3	I25.42
	I25.700-I25.799	I25.810-I25.812	I70.0-I70.1	I70.201-I70.209
	I70.211-I70.219	I70.221-I70.249	I70.25	I70.261-I70.299
	I70.301-I70.399	I70.401-I70.499	I70.501-I70.599	I70.601-I70.699
	I70.701-I70.799	I70.8	I70.90-I70.91	M00.00
	M00.011-M00.079	M00.08-M00.10	M00.111-M00.179	M00.18-M00.20
	M00.211-M00.279	M00.28-M00.29	M00.80	M00.811-M00.879

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

M01.X0	M01.X11-M01.X9	M02.10	M02.111-M02.89
M05.00	M05.011-M05.09	M05.10	M05.111-M05.9
M06.00	M06.011-M06.09	M06.1	M06.20
M06.211-M06.29	M06.30	M06.311-M06.39	M06.4
M06.80	M06.811-M06.9	M07.60	M07.611-M07.69
M07.68-M07.69	M08.00	M08.011-M08.09	M08.20
M08.211-M08.29	M08.3	M08.40	M08.411-M08.48
M08.80	M08.811-M08.90	M08.911-M08.99	M12.00-M12.259
M12.80	M12.811-M12.9	M13.0	M13.10
M13.111-M13.179	M13.80	M13.811-M13.89	M15.0-M15.59
M16.0	M16.10-M16.9	M17.0	M17.10-M17.9
M18.0	M18.10-M18.9	M19.011-M19.279	M19.90-M19.93
M1A.10X0-M1A.0X1	M1A.1110-M1A.19X1	M35.2	T56.0X1A-T56.7X4A
T56.811A-T56.94XA	T57.0X1A-T57.0X4A	T57.2X1A-T57.2X4A	T80.89XA-T80.90XA

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. FDA and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:
 - 1. Consultation with the Blue Cross and Blue Shield Association technology assessment program (TEC) or other nonaffiliated technology evaluation center(s);
 - 2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
 - 3. Reference to federal regulations.

**Medically Necessary (or "Medical Necessity") - Health care services, treatment, procedures, equipment, drugs, devices, items or supplies that a Provider, exercising prudent clinical judgment, would provide to a patient for the purpose of preventing, evaluating, diagnosing or treating an illness, injury, disease or its symptoms, and that are:

- A. In accordance with nationally accepted standards of medical practice;
- B. Clinically appropriate, in terms of type, frequency, extent, level of care, site and duration, and considered effective for the patient's illness, injury or disease; and
- C. Not primarily for the personal comfort or convenience of the patient, physician or other health care provider, and not more costly than an alternative service or sequence of services at least as likely to produce equivalent therapeutic or diagnostic results as to the diagnosis or treatment of that patient's illness, injury or disease.

For these purposes, "nationally accepted standards of medical practice" means standards that are based on credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community, Physician Specialty Society recommendations and the views of Physicians practicing in relevant clinical areas and any other relevant factors.

‡ Indicated trademarks are the registered trademarks of their respective owners.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.



Louisiana

Chelation Therapy

Policy # 00014

Original Effective Date: 06/24/2002

Current Effective Date: 12/20/2017

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

©2017 Blue Cross and Blue Shield of Louisiana

Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.